vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
21.34
+0.54 (2.61%)
May 12, 2025, 4:00 PM - Market closed

Company Description

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.

The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes.

It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases.

In addition, the company’s other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress.

It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737.

The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.

vTv Therapeutics Inc.
vTv Therapeutics logo
Country United States
Founded 2015
IPO Date Jul 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Paul Sekhri

Contact Details

Address:
3980 Premier Drive, Suite 310
High Point, North Carolina 27265
United States
Phone 336 841 0300
Website vtvtherapeutics.com

Stock Details

Ticker Symbol VTVT
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001641489
CUSIP Number 918385105
ISIN Number US9183852048
Employer ID 47-3916571
SIC Code 2834

Key Executives

Name Position
Paul J. Sekhri M.Sc. Chief Executive Officer, President and Chairman of the Board
Barry K. Brown Interim Principal Financial Officer and Chief Accounting Officer
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer and Executive Vice President
Elizabeth M. Keiley Executive Vice President and General Counsel
Richard S. Nelson Executive Vice President of Corporate Development and Director
Dr. Thomas Strack M.D., Ph.D. Chief Medical Officer
Martin Lafontaine Chief Commercial Officer

Latest SEC Filings

Date Type Title
May 1, 2025 144 Filing
Apr 29, 2025 144 Filing
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 24, 2025 144 Filing
Apr 11, 2025 8-K Current Report
Mar 31, 2025 8-K Current Report
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Mar 17, 2025 8-K Current Report
Feb 27, 2025 8-K Current Report